Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
26.86
-1.15 (-4.11%)
Delayed Quote
Updated: 3:36 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
Today 3:03 EST
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals, Inc. (IONS)
November 12, 2026
Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
November 12, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
IONS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ionis Pharmaceuticals, Inc. (IONS)
November 11, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
Ionis to present at upcoming investor conferences
November 10, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating
November 09, 2026
From
Kehoe Law Firm
Via
GlobeNewswire
Ionis reports third quarter 2026 financial results and highlights progress on key programs
November 09, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to hold third quarter 2026 financial results webcast
November 02, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
October 23, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis ranked #1 on Science’s Top Employers list
October 22, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
October 20, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
October 16, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
September 22, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 04, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
September 03, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to present at upcoming investor conferences
September 03, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
August 20, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
August 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
July 29, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
July 29, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ionis to hold second quarter 2026 financial results webcast
July 15, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
July 14, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
July 13, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
July 13, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
July 09, 2026
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today